Jeff Carter

Jeff Carter is the CEO and Founder of Scaffold Therapeutics, a company focused on drug discovery in RNA biology, particularly targeting oncology and neurodegenerative diseases. He has held this position since January 2022 and is also an Entrepreneur In Residence at Iaso Ventures, reflecting his deep involvement in the life sciences sector.

Professional Background

• Previous Roles:
  • Co-founder and COO at Arxspan (2011-2021), which was later acquired by Bruker Corporation.
  • Product Manager and Director of Major Account Sales at CambridgeSoft (2002-2010), where he managed global product responsibilities for ChemDraw.
  • Technical Lead at Amazon.com (1999-2002), where he developed IT systems management infrastructure.
  • Software Engineer at Elcom Inc. (1996-1998).

Education

Jeff holds a Bachelor of Science degree in Chemistry from the University of Massachusetts Amherst, graduating in 1995. He also briefly attended the University of Florida.

Current Focus

At Scaffold Therapeutics, Jeff is leading efforts to decode the transcriptome and develop innovative therapies. The company has recently partnered with QureALZ to advance research in Alzheimer's and other neurodegenerative disorders, leveraging its drug discovery platform.

His extensive experience in both technical and managerial roles within the life sciences industry positions him as a key figure in advancing therapeutic innovations.